Topline
Elon Musk’s Neuralink has received FDA approval to begin its “first-in-human clinical study”, the company said Thursday, a key step for the company which is attempting to develop a direct interface between the human brain and computers.
Neuralink says it has received approval from the FDA to begin human clinical trials.
Key Facts
In an announcement on Twitter, the company said the approval was a result of the Neuralink team working in “close collaboration with the FDA.”
The company noted that recruitment is not yet open for its clinical trials, but said it will announce more details about this soon.
The approval means that Neuralink appears to have resolved safety concerns that had reportedly led to the FDA rejecting its request for human trials last year.
Musk, who co-founded the company, reacted to the announcement with a tweet congratulating the Neuralink team.
Neuralink’s brain-computer interface uses thousands of small electrodes embedded in the brain to read signals emitted by neurons and transmit them to a computer.
Key Background
The timing of the approval is broadly in line with Musk’s remarks at Neuralink’s most recent event in December where said the company will be able to plant its first brain chip in a human in six months. At the event Musk and the Neuralink team demonstrated the use of the brain chips on monkeys and pigs. During the presentation, Musk claimed one of the first real-world applications for the chips could be the restoration of vision in people who have lost their eyesight or motor function in people who are dealing with paralysis. The billionaire’s ultimate goal with Neuralink, however, is to create brain chips that allow human intelligence to directly interface and eventually merge with artificial intelligence.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
